07:47 AM EDT, 09/06/2024 (MT Newswires) -- Vor Biopharma ( VOR ) said Thursday that new clinical data from its ongoing phase 1/2 study of patients with relapsed or refractory acute myeloid leukemia treated with trem-cel followed by Mylotarg validated its approach of "using shielded transplants" in delivering targeted therapies.

The data showed reliable engraftment, shielding of the blood system from Mylotarg on-target toxicity, a broadened therapeutic window for Mylotarg, and early evidence of patient benefit, the company said.

Vor said it plans to contact the Food and Drug Administration to discuss a pivotal trial design for trem-cel in combination with Mylotarg around year-end.

Shares of Vor Biopharma ( VOR ) rose by more than 9% in recent premarket trading.

Price: 0.9009, Change: +0.08, Percent Change: +9.20